September 8, 2022 | Issue #17

Good Evening

. Welcome back to another issue of Spannr. We're approaching the 6-month mark since our launch. That said, unlike past issues, it's time to do a little bit of catching up.

In this week's newsletter

:

📌 Keeping you in the loop

📢 Biz developments

💸 Fresh funding & grants

🌐 Weekend reading material

📌 Catching Up

Over the past couple of months, our readership has really begun to take off. Not only did you sign up for Spannr, but you’re now a part of something much bigger… a community dedicated to advancing healthy human lifespans.We do not take that lightly… In fact, you make this rocket ship possible. 🚀So here’s what we want to do...First, we want to personally say thank you for being patient.As you may already know, our team is in the process of building tools and resources that stretch far beyond this weekly newsletter. In other words, everything you've seen from us thus far is just one piece of the puzzle.The truth is, we're a small, bootstrapped team taking a leap of faith to demystify the entire longevity biotech space. It's no easy task, as you can imagine... but we remain up for the challenge!Secondly, because many of you have recently joined us, we wanted to take some time to highlight the progress we've made thus far. In a sense, this is a way to keep everyone up to date.So today, we’ll quickly revisit some of the recent publications that we hope can help bridge the gap between the common consumer and the longevity community.As a reminder, all written content, website resources such as our Stock Index, and future products are being built with the idea that the longevity ecosystem needs to be simplified and approachable for everyone.So, without further ado, here are some of our most-shared posts since we got into this mess:

• Analyzing One of Aging’s Biggest Dilemmas: The Lack of Government Funding

• Sneaky Spirits: An Unbiased Look at Alcohol’s Effect on Longevity

• How to Evaluate Longevity Stocks

• A Psychedelic Nexus: Veterans, PTSD, and Longevity

• Former Silicon Valley Tech Pros, Now Targeting Longevity

• Barking Up the Right Tree: How Dogs Just Might Be the Key to Human Longevity

• How Longevity Research is Being Disrupted by Crypto

• Hevolution Foundation: Longevity’s Watershed Moment?

We’ve got much, much more coming soon. Please feel free to reach out with any questions, comments, or suggestions… especially if you are involved in the industry and want to get a sneak peek at some of the tools we are building 🤫.Until then, thank you again for your support, and look forward to many more longevity insights.

• Glucose monitor developer Know Labs files and sets terms for a $6 million NYSE American uplisting

• Athersys (ATHX) Announces 1-for-25 Reverse Stock Split

• ChromaDex (CDXC) Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales into Brazil

• FDA Grants Fast Track Designation for Longeveron’s (LGVN) Lomecel-B Product

• State of Biopharma Tech Q2’22 Report (CB Insights)

• Health insurers just published close to a trillion hospital prices (DoltHub)

• So, maybe a little rapamycin goes a long way – or at least a lot farther than we thought? (Methuselah Foundation)

• Training the next generation of geroscience researchers (NIA Division of Aging Biology)

• Ketone bodies: Likely good for aging—and maybe for the military too (Buck Institute)

• First U.S. patient receives autologous stem cell therapy to treat dry AMD (National Institutes of Health)

• NUS Yong Loo Lin School of Medicine receives $5 million from the Lien Foundation

• Lento Bio raises $680,000 in oversubscribed seed round led by Ichor Life Sciences

• L1 Digital & Shine Capital express interest in VitaDAO

• A long Covid collaborative kicks off with $15 million to study causes of lingering disease, conduct clinical trials

• Diadem, a company developing blood-based tests for early predictions of Alzheimer's Disease receives a $2.5 million NIH SBIR Grant

• Transdermal Diagnostics secures £1.1 million to develop the world’s first needle-free platform for blood sugar monitoring

• UC San Diego Sanford Stem Cell Institute receives $150 million in new funding to combine current efforts with new programs intended to leverage space-based science

Performance:

Latest Price: $142.097d-Return: +9.02%Market Cap: $12.12b

Key Drivers:

Denali (DNLI): +13.90%Recursion (RXRX): +17.92%Humacyte (HUMA): +11.24%